OpenNashEarnings

Edwards Lifesciences (EW) · Medical Devices

Edwards Lifesciences Q3 2026 earnings: summary, key numbers & outlook

Results filed 4 Nov 2026 · Quarter ended 30 Sep 2026

Official transcript (PDF) ↗Press release ↗Investor relations ↗

Summaries and transcripts are machine-generated and can contain errors.

In brief

Edwards raised its 2026 outlook after TAVR share gains and a new CMS coverage decision, while TMTT growth from PASCAL and EVOQUE added a second structural heart engine.

Edwards' TAVR business grew on a heightened clinical focus on treating aortic stenosis earlier, with modest share gains and stable pricing. CMS finalized an updated TAVR coverage policy, and Japan granted dedicated reimbursement for SAPIEN 3 Ultra RESILIA. In mitral and tricuspid, mitral and tricuspid procedure volumes grew in double digits, and the FDA approved PASCAL Ace with Capture Clarity and PASCAL Precision for tricuspid.

Management says growth from here should come mainly from rising procedure volumes rather than share gains, and it is steering toward earlier-stage disease, with the PROGRESS trial in moderate aortic stenosis as a turning point. The tension is that share gains are fading as a driver, so growth depends on the market expanding. New launches are also being rolled out in a measured way, which limits how fast they can add to growth.

Key numbers

Net sales · GAAP
$1.7B

up 10.5% from a year ago

Net income · GAAP
$301.4M

up from $290.3 a year ago

Gross profit margin · GAAP
78.5%

vs 77.9% adjusted a year ago (78.7% adjusted this quarter)

Operating income · GAAP
$299.1M

vs $307.1 a year ago

Operating profit margin · GAAP
17.4%

30.3% adjusted

Segment or metricValueChange
TAVR$1.2Bup 8.0%, 8.8% constant currency
TMTT$209.5Mup 44.3%, 45.9% constant currency
Surgical$264.4Mup 2.5%, 2.8% constant currency
United States$1.0Bup 11.0%
Europe$414.6Mup 6.9%, 8.2% constant currency
Japan$92.0Mup 2.2%, 12.2% constant currency
Rest of World$201.3Mup 20.2%, 18.3% constant currency
Where each number comes from
  • Net sales: “Net sales | $1,715.5 | $1,553.1 | $5,105.1 | $4,498.0 Cost of sales | 369.2 | 345.2 | 1,124.2 | 991.2 Gross profit”
  • Net income: “Loss from discontinued operations, net of tax | — | (2.0) | — | (13.6) Net income | 301.4 | 290.3 | 923.5 | 978.2”
  • Gross profit margin: “For the quarter, gross profit margin was 78.5%, or 78.7% adjusted compared to 77.9% in the same period last year.”
  • Operating income: “Operating income, net | 299.1 | 307.1 | 1,289.9 | 1,113.1”
  • Operating profit margin: “Operating profit margin in the third quarter was 17.4%, or 30.3% adjusted.”
  • TAVR: “Transcatheter Aortic Valve Replacement | $1,241.6 | $1,149.9 | $91.7 | 8.0% | $(7.9) | $1,142.0 | 8.8%”
  • TMTT: “Transcatheter Mitral and Tricuspid Therapies (A) | 209.5 | 145.2 | 64.3 | 44.3% | (1.5) | 143.7 | 45.9%”
  • Surgical: “Surgical (B) | 264.4 | 258.0 | 6.4 | 2.5% | (0.4) | 257.6 | 2.8%”
  • United States: “United States | $1,007.6 | $907.5 | $100.1 | 11.0% | $— | $907.5 | 11.0%”
  • Europe: “Europe | 414.6 | 387.9 | 26.7 | 6.9% | (4.3) | 383.6 | 8.2%”
  • Japan: “Japan | 92.0 | 90.1 | 1.9 | 2.2% | (8.1) | 82.0 | 12.2%”
  • Rest of World: “Rest of World | 201.3 | 167.6 | 33.7 | 20.2% | 2.6 | 170.2 | 18.3%”

Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.

From the filingQ3 2026vs year agovs last quarter
Revenue$1.7B+10.5%−1.5%
Operating income$299.1M−2.6%−41.7%
Net income$307.5M+5.6%+27.1%
Diluted EPS$0.53+6.0%+26.2%
Free cash flow$506.7M−1.8%−13.4%
Gross margin78.5%+0.7 pts+1.0 pts
Operating margin17.4%−2.4 pts−12.1 pts

Calculated by code from XBRL, not by the model.

Guidance check

MetricOutlook given with Q2 2026ReportedResult
Revenuebetween $1.63 and $1.71 billion$1.7Babove the range

Compared with the company's own guidance, not analyst estimates, and only where the outlook and the reported figure are the same measure on the same basis. Ranges are worked out by code from the company's wording. How this works.

Outlook

MetricPeriodOutlook
Q4 total salesfourth quarter of 2026$1.67 and $1.75 billion
Q4 adjusted EPSfourth quarter of 2026$0.61 to $0.69
Total company sales growth2026approximately 11.5%
TAVR sales growth20269.0% to 9.5%
TMTT sales2026$780 to $790 million
Adjusted EPS2026$2.97 to $3.05
Adjusted gross margin202678% to 79%
R&D as a percentage of sales2026approximately 16.5%

Key takeaways

  1. Moderate AS evidence marks a turning point

    The PROGRESS trial was presented at TCT and published in The New England Journal of Medicine, which Edwards calls a turning point in managing moderate aortic stenosis. It supports the push toward earlier intervention and a larger treatable population.

  2. CMS finalized an updated TAVR coverage policy

    The final national coverage determination aims to expand timely, high-quality access to care and reinforces the multidisciplinary heart team. It is a policy step Edwards names among its priorities for the quarter.

  3. PASCAL approvals widen the mitral and tricuspid toolkit

    FDA approved PASCAL Ace with Capture Clarity for degenerative mitral TEER and PASCAL Precision for tricuspid regurgitation, with early clinician feedback described as very positive. The CLASP IITR trial showed PASCAL plus medical therapy was superior to medical therapy alone.

  4. TAVR growth shifts from share gains to volume

    Edwards cites modest share gains, stable pricing and strong SAPIEN 3 Ultra RESILIA adoption, plus new dedicated reimbursement in Japan. Management now expects growth to come mainly from procedure volumes, not share gains.

  5. EVOQUE and SAPIEN M3 extend replacement options

    EVOQUE gained U.S. and European approval for transjugular access, and SAPIEN M3 with RESILIA tissue was introduced in Europe. Edwards sees strong demand for SAPIEN M3 in patients unsuitable for mitral TEER.

Charts

Revenue$1.7B+10.5% y/yQ3 2026
Q4 2024: $1.4BQ4 ’24$1.4BQ1 2025: $1.4BQ1 ’25$1.4BQ2 2025: $1.5BQ2 ’25$1.5BQ3 2025: $1.6BQ3 ’25$1.6BQ4 2025: $1.6B (worked out from the annual figure)Q4 ’25$1.6BQ1 2026: $1.6BQ1 ’26$1.6BQ2 2026: $1.7BQ2 ’26$1.7BQ3 2026: $1.7BQ3 ’26$1.7B

Fourth quarter worked out from the annual figure.

Data
Q4 2024$1.4B
Q1 2025$1.4B
Q2 2025$1.5B
Q3 2025$1.6B
Q4 2025$1.6B *
Q1 2026$1.6B
Q2 2026$1.7B
Q3 2026$1.7B
Diluted EPS (GAAP)$0.53+6.0% y/yQ3 2026
Q4 2024: $0.65Q4 ’24$0.65Q1 2025: $0.61Q1 ’25$0.61Q2 2025: $0.56Q2 ’25$0.56Q3 2025: $0.50Q3 ’25$0.50Q1 2026: $0.66Q1 ’26$0.66Q2 2026: $0.42Q2 ’26$0.42Q3 2026: $0.53Q3 ’26$0.53
Data
Q4 2024$0.65
Q1 2025$0.61
Q2 2025$0.56
Q3 2025$0.50
Q1 2026$0.66
Q2 2026$0.42
Q3 2026$0.53

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin17.4%−2.4 pts y/yQ3 2026
Q4 2024: 22.6%Q4 ’2422.6%Q1 2025: 27.9%Q1 ’2527.9%Q2 2025: 26.8%Q2 ’2526.8%Q3 2025: 19.8%Q3 ’2519.8%Q4 2025: 9.6%Q4 ’259.6%Q1 2026: 29.0%Q1 ’2629.0%Q2 2026: 29.5%Q2 ’2629.5%Q3 2026: 17.4%Q3 ’2617.4%
Data
Q4 202422.6%
Q1 202527.9%
Q2 202526.8%
Q3 202519.8%
Q4 20259.6%
Q1 202629.0%
Q2 202629.5%
Q3 202617.4%
Free cash flow$506.7M−1.8% y/yQ3 2026
Q4 2024: -$177.3MQ4 ’24-$177.3MQ1 2025: $224.4MQ1 ’25$224.4MQ2 2025: $240.9MQ2 ’25$240.9MQ3 2025: $516.2MQ3 ’25$516.2MQ4 2025: $353.5MQ4 ’25$353.5MQ1 2026: -$21.1MQ1 ’26-$21.1MQ2 2026: $585.0MQ2 ’26$585.0MQ3 2026: $506.7MQ3 ’26$506.7M
Data
Q4 2024-$177.3M
Q1 2025$224.4M
Q2 2025$240.9M
Q3 2025$516.2M
Q4 2025$353.5M
Q1 2026-$21.1M
Q2 2026$585.0M
Q3 2026$506.7M

Operating cash flow minus capital expenditure, from cash flow statements.

Questions

What is driving Edwards' TAVR growth?

Procedure growth from a heightened focus on proactive treatment of severe aortic stenosis, modest share gains, and stable pricing. Growth rates were similar in the U.S. and outside it.

Which new products did Edwards win approval for this quarter?

PASCAL Ace with Capture Clarity (U.S.), PASCAL Precision for tricuspid (U.S.), SAPIEN M3 RESILIA (Europe), EVOQUE transjugular access (U.S. and Europe), and AUTUS for pediatric patients (U.S.).

Why does the PROGRESS trial matter?

It was presented at TCT and published in The New England Journal of Medicine, and Edwards says it marks a turning point in the management of moderate aortic stenosis.

How are mitral and tricuspid therapies performing?

Mitral and tricuspid procedure volumes continued to grow in the double digits, with the PASCAL, EVOQUE and SAPIEN M3 systems all contributing, and TMTT guidance was raised to $780 to $790 million.

What does management expect to drive growth going forward?

Edwards assumes growth in the fourth quarter and beyond will come mainly from increasing procedure volumes rather than share gains, with positive TAVR procedure trends seen exiting the quarter.

Documents

From Edwards Lifesciences investor relations

SEC filing

Call recording

Call recording on YouTube ↗. Official replay ↗.

Read Edwards Lifesciences's official transcript ↗.